These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 37660116)

  • 1. Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.
    Pytell JD; Fojo AT; Keruly JC; Snow LN; Falade-Nwulia O; Moore RD; Chander G; Lesko CR
    Addict Sci Clin Pract; 2023 Sep; 18(1):51. PubMed ID: 37660116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
    Wakeman SE; McGovern S; Kehoe L; Kane MT; Powell EA; Casey SK; Yacorps GM; Irvin JR; Rodriguez W; Regan S
    J Subst Abuse Treat; 2022 Oct; 141():108848. PubMed ID: 35926256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
    Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
    Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: A retrospective cohort study.
    Selitsky L; Nordeck C; Truong A; Agus D; Buresh ME
    J Subst Use Addict Treat; 2023 Apr; 147():208981. PubMed ID: 36804350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
    J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV.
    Wyse JJ; Robbins JL; McGinnis KA; Edelman EJ; Gordon AJ; Manhapra A; Fiellin DA; Moore BA; Korthuis PT; Gaither JR; Gordon K; Skanderson M; Barry DT; Crystal S; Justice A; Kraemer KL
    Drug Alcohol Depend; 2019 May; 198():70-75. PubMed ID: 30878769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018.
    Weinstein LC; Iqbal Q; Cunningham A; Debates R; Landistratis G; Doggett P; Silverio A
    Am J Public Health; 2020 Apr; 110(4):580-586. PubMed ID: 32078355
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
    Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
    JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.
    Parlier-Ahmad AB; Pugh M; Martin CE
    J Racial Ethn Health Disparities; 2022 Aug; 9(4):1557-1567. PubMed ID: 34254271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests.
    Bagley SM; Cheng DM; Winter M; Alford DP; LaBelle C; Walley AY; Samet JH
    Drug Alcohol Depend; 2018 Nov; 192():245-249. PubMed ID: 30290291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
    Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
    J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment.
    Hill K; Nussdorf L; Mount JD; Silk R; Gross C; Sternberg D; Bijole P; Jones M; Kier R; Mccullough D; Mathur P; Kottilil S; Masur H; Kattakuzhy S; Rosenthal ES
    J Addict Med; 2022 Jan-Feb 01; 16(1):10-17. PubMed ID: 33560694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
    Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.
    Bailey SR; Lucas JA; Angier H; Cantone RE; Fleishman J; Garvey B; Cohen DJ; Rdesinski RE; Gordon L
    J Subst Abuse Treat; 2021 Dec; 131():108548. PubMed ID: 34244013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder.
    Beck L; Parlier-Ahmad AB; Martin CE
    J Subst Abuse Treat; 2022 Jan; 132():108506. PubMed ID: 34098202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.